Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

Becoming a Life Sciences Lawyer – The View From Goodwin (Chambers Associate)

Related Content

A Direct Line Between Regulators: What the New SEC-FDA Information-Sharing MOU Means for Life Sciences Companies

Eli Lilly to Acquire Merida Biosciences

AbbVie Submits Regulatory Application to EMA for Subcutaneous SKYRIZI®

Takeda Files BPCIA Suit Against Alvotech for Vedolizumab Biosimilar

Alvotech and Lotus Enter Agreement for Durvalumab and Emicizumab Biosimilars

FDA Approves Ultragenyx’s GENGLYCOS™ Gene Therapy for GSDIa

FDA approves Regeneron’s PASATRU™ (garetosmab-grts) for Fibrodysplasia Ossificans Progressiva

FDA Addresses FAQs on Developing Potential Cellular and Gene Therapy Products

Goodwin Pharma Services Symposium

Second Annual AI & Drug Discovery Symposium: Revolutionizing the Future of Medicine

Goodwin Strengthens Life Sciences and Public M&A Platform With Partner Ro Park

Goodwin Advises Mission BioCapital on Securing Eligibility for $44.5 Million Non-Dilutive Funding Through AMED Program

Goodwin Advises Moderna in $3 Billion 0.00% Convertible Senior Notes Offering and Capped Call

Goodwin Advises Merida Biosciences in up to $2.875 Billion Acquisition by Eli Lilly

Goodwin Advises Aureka Biotechnologies on Intellectual Property Aspects for $100 Million Series B

Goodwin Advises Amylyx Pharmaceuticals on $575 Million Public Offering

Life Sciences

Intellectual Property